Currently, SGLT2 inhibitors form part of the guideline-recommended standard-of-care in the treatment of heart failure will various ejection fractions, as they have demonstrated benefits in cardiac and renal protection, independent of HbA1c, blood pressure, weight, and kidney function [1,2]. In heart failure trials, women are mostly underrepresented leading to a lack of sex-specific cardiovascular (CV) outcome data [1,3]. To gain further insight into this matter, Dr Mounica Vorla (University of Louisville School of Medicine, KY, USA) performed a meta-analysis of randomised, placebo-controlled trials that provided results stratified by sex [1]. Pooled risk ratios (RR) for the primary composite outcomes were determined using a random effects model that included data from 11 studies.
For women, this comparison of SGLT inhibition with placebo led to a pooled RR of 0.76 (95% CI 0.69–0.82; P<0.00001). The respective finding for men obtained a pooled RR of 0.80 (95% CI 0.73–0.87; P<0.00001). Furthermore, the results of the meta-analysis observed reductions in all-cause and CV death, along with hospitalisation for heart failure. Of note, the study authors conceded some limitations to their analysis. Among them the lack of patient-level data and heterogeneity between the included trials.
- Vorla M, et al. SGLT2 inhibitors in women and cardiovascular outcomes - meta-analysis of sex differences in eleven randomised controlled clinical trials. Session 1039-11, ACC 2024 Scientific Session, 6–8 April, Atlanta, USA.
- Rosano G, et al. Card Fail Rev. 2020:6:e31.
- Bozkurt B, Khalaf S. Methodist Debakey Cardiovasc J. 2017;13(4):216-223.
Medical writing support was provided by Karin Drooff, MPH
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Microaxial flow pump safes lives but comes with a price tag Next Article
Peripheral artery disease: procedure-guidance by IVUS superior to angiography »
« Microaxial flow pump safes lives but comes with a price tag Next Article
Peripheral artery disease: procedure-guidance by IVUS superior to angiography »
Table of Contents: ACC 2024
Featured articles
Matters of the heart: late-breaking news from the American College of Cardiology
KARDIA-2: Add-on zilebesiran effectively lowers blood pressure
STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes
Online First
IVUS-guided PCI beats angiography in patients with acute coronary syndrome
To stent or not to stent? Favourable results for preventive PCI in vulnerable atherosclerotic plaques
Peripheral artery disease: procedure-guidance by IVUS superior to angiography
SGLT2 inhibition in heart failure more advantageous for women than men
Microaxial flow pump safes lives but comes with a price tag
KARDIA-2: Add-on zilebesiran effectively lowers blood pressure
Safety of TAVI non-inferior to SAVR in patients with lower surgical risk
New PCSK9 inhibitor achieves LDL-C goals in high-risk and very high-risk patients
Protein drinks and exercise intervention improve physical performance in frail patients undergoing TAVR
AEGIS-II: Negative primary endpoint but infusions might benefit subgroups of patients
STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes
RELIEVE-HF: Inter-atrial shunt might be advantageous in HFrEF
BE ACTIVE shows that small incentives increase daily steps in high-risk patients
“Inclisiran first” strategy highly effective regarding LDL control in ASCVD
Olezarsen highly effective in lowering triglycerides
Related Articles
October 27, 2022
High-dose influenza vaccine: mortality benefit?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy